nach oben

Endocrine

Erschienen in:

07.09.2017 | Original Article

Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?

verfasst von: Chen-Tian Shen, Xin-Yun Zhang, Zhong-Ling Qiu, Zhen-Kui Sun, Wei-Jun Wei, Hong-Jun Song, Quan-Yong Luo

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The relationship between thyroid autoimmunity and thyroid cancer remains controversial. The objective of this study is to comprehensively analyze the association between thyroid autoimmune antibodies and disease statuses of papillary thyroid carcinoma (PTC).

Methods

Patients were divided into different groups according to their final diagnoses after radioiodine therapy as well as their serum anti-thyroglobulin antibody (TgAb) and anti-thyroidperoxidase antibody (TPOAb) titers. Clinicopathologic characteristics were then compared between groups.

Results

In all, 1126 PTC patients met the inclusion criteria. When compared with thyroid autoimmune antibody negative group, patients in positive group were young female predominant. After age and gender adjusted, patients in thyroid autoimmune antibody positive group had much more cervical metastatic node count and this effect was limited to the central compartment but not to the lateral compartment. Antibody positivity rate was much lower in patients with distant metastasis and multivariable logistic regression analysis showed positive status of antibody was a protective factor of distant metastasis of PTC with an OR value of 0.403 (95% CI 0.216–0.622, p < 0.001). Additionally, subgroup analysis demonstrated single TgAb positivity and combined positivity of TgAb and TPOAb were shown to be related to less distant metastatic disease.

Conclusions

Positive thyroid auto-antibody status could be a risk factor of more metastatic cervical lymph nodes while a protective factor of distant metastatic disease in PTC patients. The association between thyroid autoimmunity and thyroid cancer can be patient and antibody specific. A systemic immunosupression status may exist in PTC patients with distant metastasis.

Nur mit Berechtigung zugänglich

C.G. Joseph, E. Darrah, A.A. Shah, A.D. Skora, L.A. Casciola-Rosen, F.M. Wigley, F. Boin, A. Fava, C. Thoburn, I. Kinde, Y. Jiao, N. Papadopoulos, K.W. Kinzler, B. Vogelstein, A. Rosen, Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167), 152–157 (2014). https://doi.org/10.1126/science.1246886 CrossRefPubMed

G. Azizi, J.M. Keller, M. Lewis, K. Piper, D. Puett, K.M. Rivenbark, C.D. Malchoff, Association of Hashimoto’s thyroiditis with thyroid cancer. Endocr. Relat. Cancer 21(6), 845–852 (2014). https://doi.org/10.1530/ERC-14-0258 CrossRefPubMedPubMedCentral

M.R. Galdiero, G. Varricchi, G. Marone, The immune network in thyroid cancer. Oncoimmunology 5(6), e1168556 (2016). https://doi.org/10.1080/2162402X.2016.1168556 CrossRefPubMedPubMedCentral

S.I. Noureldine, R.P. Tufano, Association of Hashimoto’s thyroiditis and thyroid cancer. Curr. Opin. Oncol. 27(1), 21–25 (2015). https://doi.org/10.1097/CCO.0000000000000150 CrossRefPubMed

J.H. Lee, Y. Kim, J.W. Choi, Y.S. Kim, The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur. J. Endocrinol. 168(3), 343–349 (2013). https://doi.org/10.1530/EJE-12-0903 CrossRefPubMed

B. Jankovic, K.T. Le, J.M. Hershman, Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J. Clin. Endocrinol. Metab. 98(2), 474–482 (2013). https://doi.org/10.1210/jc.2012-2978 CrossRefPubMed

J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87(2), 489–499 (2002). https://doi.org/10.1210/jcem.87.2.8182 CrossRefPubMed

K.C. Loh, F.S. Greenspan, F. Dong, T.R. Miller, P.P. Yeo, Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84(2), 458–463 (1999). https://doi.org/10.1210/jcem.84.2.5443 CrossRefPubMed

S.L. Souza, L.V. Montalli Da Assumpcao, L.S. Ward, Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13(5), 491–495 (2003). https://doi.org/10.1089/105072503322021160 CrossRefPubMed

10.

I. Donangelo, A.E. Walts, C. Bresee, G.D. Braunstein, Lymphocytic thyroiditis is associated with increased number of benign cervical nodes and fewer central neck compartment metastatic lymph nodes in patients with differentiated thyroid cancer. Endocr. Pract. (2016). https://doi.org/10.4158/EP151078.OR

11.

X. Wu, Y. Lun, H. Jiang, Q. Gang, S. Xin, Z. Duan, J. Zhang, Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine 46(3), 554–560 (2014). https://doi.org/10.1007/s12020-013-0121-x CrossRefPubMed

12.

G.A. Lupoli, O.E. Okosieme, C. Evans, P.M. Clark, A.J. Pickett, L.D. Premawardhana, G. Lupoli, J.H. Lazarus, Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 100(1), 100–108 (2015). https://doi.org/10.1210/jc.2014-2725 CrossRefPubMed

13.

C. Durante, S. Tognini, T. Montesano, F. Orlandi, M. Torlontano, E. Puxeddu, M. Attard, G. Costante, S. Tumino, D. Meringolo, R. Bruno, F. Trulli, M. Toteda, A. Redler, G. Ronga, S. Filetti, F. Monzani, P.T.C.S. Group, Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 24(7), 1139–1145 (2014). https://doi.org/10.1089/thy.2013.0698 CrossRefPubMedPubMedCentral

14.

M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Eng. J. Med. 338(5), 297–306 (1998). https://doi.org/10.1056/NEJM199801293380506 CrossRef

15.

Z.L. Qiu, H.J. Song, Y.H. Xu, Q.Y. Luo, Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96(10), 3078–3086 (2011). https://doi.org/10.1210/jc.2011-0093 CrossRefPubMed

16.

C.T. Shen, Z.L. Qiu, Q.Y. Luo, Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr. Relat. Cancer 21(2), 253–261 (2014). https://doi.org/10.1530/ERC-13-0438 CrossRefPubMed

17.

H.J. Song, Z.L. Qiu, C.T. Shen, W.J. Wei, Q.Y. Luo, Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur. J. Endocrinol. 173(3), 399–408 (2015). https://doi.org/10.1530/EJE-15-0296 CrossRefPubMed

18.

K.C. Bible, M. Ryder, Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat. Rev. Clin. Oncol. 13(7), 403–416 (2016). https://doi.org/10.1038/nrclinonc.2016.19 CrossRefPubMed

19.

C.T. Shen, W.J. Wei, Z.L. Qiu, H.J. Song, Q.Y. Luo, Value of post-therapeutic (1)(3)(1)I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. Endocrine 51(2), 283–290 (2016). https://doi.org/10.1007/s12020-015-0660-4 CrossRefPubMed

20.

J.K. Chung, Y.J. Park, T.Y. Kim, Y. So, S.K. Kim, D.J. Park, D.S. Lee, M.C. Lee, B.Y. Cho, Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol. 57(2), 215–221 (2002)CrossRef

21.

M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet 2(5), 356–358 (2014). https://doi.org/10.1016/S2213-8587(13)70215-8 PubMed

22.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016). 10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

23.

I. Vasileiadis, G. Boutzios, G. Charitoudis, E. Koukoulioti, T. Karatzas, Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann. Surg. Oncol. 21(8), 2725–2732 (2014). https://doi.org/10.1245/s10434-014-3593-x CrossRefPubMed

24.

E.S. Kim, D.J. Lim, K.H. Baek, J.M. Lee, M.K. Kim, H.S. Kwon, K.H. Song, M.I. Kang, B.Y. Cha, K.W. Lee, H.Y. Son, Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 20(8), 885–891 (2010). https://doi.org/10.1089/thy.2009.0384 CrossRefPubMed

25.

S. Dvorkin, E. Robenshtok, D. Hirsch, Y. Strenov, I. Shimon, C.A. Benbassat, Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J. Clin. Endocrinol. Metab. 98(6), 2409–2414 (2013). https://doi.org/10.1210/jc.2013-1309 CrossRefPubMed

26.

M.B. Bernstein, S. Krishnan, J.W. Hodge, J.Y. Chang, Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13(8), 516–524 (2016). https://doi.org/10.1038/nrclinonc.2016.30 CrossRefPubMed

27.

I. Okayasu, M. Fujiwara, Y. Hara, Y. Tanaka, N.R. Rose, Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 76(11), 2312–2318 (1995)CrossRefPubMed

28.

S.D. Larson, L.N. Jackson, T.S. Riall, T. Uchida, R.P. Thomas, S. Qiu, B.M. Evers, Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J. Am. Coll. Surg. 204(5), 764–773 (2007). https://doi.org/10.1016/j.jamcollsurg.2006.12.037. discussion 773-765CrossRefPubMedPubMedCentral

29.

C. Anil, S. Goksel, A. Gursoy, Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 20(6), 601–606 (2010). https://doi.org/10.1089/thy.2009.0450 CrossRefPubMed

30.

M.G. Castagna, V. Belardini, S. Memmo, F. Maino, A. Di Santo, P. Toti, A.F. Carli, G. Caruso, F. Pacini, Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J. Clin. Endocrinol. Metab. 99(9), 3193–3198 (2014). https://doi.org/10.1210/jc.2014-1302 CrossRefPubMed

31.

G. Grani, A. Calvanese, G. Carbotta, M. D’Alessandri, A. Nesca, M. Bianchini, M. Del Sordo, M. Vitale, A. Fumarola, Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. Head Neck 37(2), 260–264 (2015). https://doi.org/10.1002/hed.23587 CrossRefPubMed

Titel: Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?
verfasst von: Chen-Tian Shen
Xin-Yun Zhang
Zhong-Ling Qiu
Zhen-Kui Sun
Wei-Jun Wei
Hong-Jun Song
Quan-Yong Luo
Publikationsdatum: 07.09.2017
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1401-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

The cellular selection between apoptosis and autophagy: roles of vitamin D, glucose and immune response in diabetic nephropathy

The dual role of group V secretory phospholipase A2 in pancreatic β-cells

Development of metabolic syndrome in high-sucrose diet fed rats is not associated with decrease in adiponectin levels

Increased serum levels of fetuin B in patients with coronary artery disease

The impact of peri-operative dexamethasone administration on the normal hypothalamic pituitary adrenal response to major surgical procedures